Navigation Links
Exenatide Clinical Data Analysis Shows No Increased Risk of Cardiovascular Events
Date:3/26/2009

Large Cardiovascular Outcomes Study To Be Initiated

Manufacturing Comparability Analysis Complete: Exenatide Once Weekly NDA Submission Remains On Track

SAN DIEGO, INDIANAPOLIS, and CAMBRIDGE, Mass., March 26 /PRNewswire-FirstCall/ -- Amylin Pharmaceuticals, Inc., (Nasdaq: AMLN), Eli Lilly and Company (NYSE: LLY) and Alkermes, Inc. (Nasdaq: ALKS) today announced that a meta-analysis of primary cardiovascular events across controlled clinical studies of three months or greater, from the BYETTA(R) (exenatide) injection database, showed no increased risk of cardiovascular events associated with exenatide use. This analysis was done in a manner consistent with U.S. Food and Drug Administration's (FDA's) updated guidance for evaluating cardiovascular risk in type 2 diabetes agents. Results of this analysis indicate that the relative risk of cardiovascular events in exenatide-treated patients, compared to controls, was 0.70 with a 95 percent confidence interval of 0.38 - 1.31. In this analysis, cardiovascular events included cardiovascular mortality, myocardial infarction, stroke, hospitalization for acute coronary syndrome and revascularization procedures. This finding suggests there is no increased risk of exenatide on cardiovascular outcomes and will be used to support the cardiovascular safety of exenatide once weekly, a phase 3 investigational formulation of exenatide, the active ingredient in BYETTA.

To determine if there are favorable cardiovascular effects of exenatide treatment, Lilly and Amylin intend to initiate a large cardiovascular outcomes trial with a superiority design that will evaluate the effects of exenati
'/>"/>

SOURCE Amylin Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5 6 7 8

Related biology technology :

1. New Data From Head-to-Head Phase 3 Trial Demonstrate That Liraglutide is More Effective Than Exenatide in Treatment of Type 2 Diabetes
2. Lilly and Amylin Enter Into Supply Agreement for Exenatide Once Weekly
3. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
4. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
5. Romark Initiates Clinical Trial of Alinia(R) for Chronic Hepatitis C in the United States
6. The Multiple Myeloma Research Consortium (MMRC) and Proteolix Initiate Phase 2 Clinical Trial Investigating Carfilzomib for the Treatment of Multiple Myeloma
7. PNH Patients Treated with Soliris(TM) Experienced Dramatic Reduction in Blood Clots During Clinical Trials
8. Clinical Data Acquires Epidauros Biotechnologie AG, Significantly Enhancing Proprietary Genetic Biomarker Portfolio
9. ExonHit Therapeutics: Allergan and ExonHits First Collaboration Compound to Begin Human Clinical Trials
10. Sunesis Pharmaceuticals Announces Reorganization to Focus Resources and Build Value in Clinical-Stage Programs
11. Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/20/2013)... (PRWEB) June 20, 2013 The ... outcomes measurement because of variability in Patient-Reported Outcomes ... sensitivity of such scales to culture, their cross-cultural ... laboratory testing for the successful development of a ... steps for maximizing cross-cultural equivalence of scales assessing ...
(Date:6/20/2013)... 20, 2013 Based on its recent ... Sullivan presents bitop AG with the 2013 European ... The company,s path-breaking extremolyte platform enables a naturally-derived ... dry eye or dry nose syndrome, and respiratory ... to revolutionize how allergies are treated. ...
(Date:6/20/2013)... June 20, 2013 Over the years, ... has received many questions that can be summed up in ... Owner of GLM Displays, Matt Lunser, sat down and ... between his products and offer some useful tips on how ... , “This buyer's guide is meant to help our clients ...
(Date:6/20/2013)... Belatrix Software, the leading global Nearshore Agile ... latest initiative – the Belatrix Software Innovation University (BSIU). ... and business and technology executives to participate in a ... the initiative is to fuel business leaders with what ... innovation efforts. It’s that inspiration that has the ...
Breaking Biology Technology:Cross-Cultural Qualitative Research for Simultaneous Scale Development, New Life Science Webinar Hosted by Xtalks 2Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market 2Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market 3Frost & Sullivan Presents bitop AG with the 2013 New Product Innovation Award in the Extremolytes Therapeutics Market 4Belatrix Software Kicks off Major Innovation Effort and Invites Innovation Expert to Share How Agile + Design Thinking Accelerate Product Innovation 2
... 2011 K-V Pharmaceutical Company (NYSE:  KVa/KVb) announced today ... divest Nesher Pharmaceuticals, Inc., its generics subsidiary, and the ... Inc. for approximately $60 million in cash. The transaction ... KV,s 2012 fiscal year, subject to customary closing conditions. ...
... they left a trail of breadcrumbs to find their ... System (GPS), WiFi, and Bluetooth are the digital signals ... helping us find our location and map our routes. ... few exceptions, today,s firefighters still rely on 20th-century radios, ...
... Background : The U.S. House of Representatives ... appropriations bill, co-sponsored by Rep. Don Young (R-AK) and Rep. ... Drug Administration approval of salmon grown from AquaBounty Technologie,s AquAdvantage ... ten of the total 435 House members. ...
Cached Biology Technology:K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 2K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 3K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 4K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 5K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 6K-V Pharmaceutical Announces Divestiture of Generics Business to Zydus 7Wireless 'breadcrumbs' that wont become toast when baked...or soggy when hosed 2Wireless 'breadcrumbs' that wont become toast when baked...or soggy when hosed 3Statement by Ronald L. Stotish, Ph.D., President and CEO of AquaBounty Technologies 2
(Date:6/19/2013)... , June 20, 2013 Based ... market, Frost & Sullivan recognizes geneOnyx Limited with ... New Product Innovation. geneOnyx leverages a DNA testing ... create an on-the-spot genetic test for anti-aging cosmetics. ... DNA collection procedure from saliva to examine single ...
(Date:6/19/2013)... network in Tanzania is playing a vital role in ... west in response to climate and environmental changes, according ... Using data on savannah birds from the Tanzanian Bird ... over recent decades - the researchers found that they ... move to areas further west where dry seasons are ...
(Date:6/19/2013)... 2013   Mercy Medical Center ... for conducting on-demand, Hemoglobin A 1c ... as analysis of important red blood cell, ... new system enables the hospital to provide ... and their patients, which can improve treatment ...
Breaking Biology News(10 mins):Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 2Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 3Frost & Sullivan Applauds geneOnyx for its DNA Testing Solution for the Personalized Cosmeceuticals Market 4Protected areas provide African birds with stepping stones to survival 2Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 2Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 3Mercy Lab Offers Faster On-demand Diabetes Testing, Cellular Studies 4
... In much of Africa, a herd of cattle is ... dowry, funeral fund, symbol of wealth, and hedge against drought. ... cow to disease can spell ruin. Yet a grievous ... puts annual losses from disease at $40 billion, some twenty-five ...
... HOUSTON -- (Aug. 17, 2010) -- The most robust statistical ... Eve" -- the maternal ancestor of all living humans -- ... University study was based on a side-by-side comparison of 10 ... lived using a very different set of assumptions about the ...
... could lead to a brand new class of drugs to ... and back pain without numbing the whole body. ... Council (BBSRC) and working at UCL (University College London), have ... pain are regulated by molecules inside cells called small RNAs. ...
Cached Biology News:Cow vaccines go vroom 2Cow vaccines go vroom 3Mother of all humans lived 200,000 years ago 2Mother of all humans lived 200,000 years ago 3Scientists uncover Achilles heel of chronic inflammatory pain 2
... Shimadzus GCMS-QP2010s Gas Chromatograph/Mass Spectrometer, utilizing ... the GCMS-QP2010 Plus, offers high throughput ... an excellent performance-to-cost ratio. Like the ... constant linear velocity for optimum separation, ...
... combines a single-channel sample processing head, an ... reagent dispenser all in one compact, affordable ... pipette tips, the Precision XS autoclavable and ... available for transferring larger volumes. Intuitive Precision ...
... world of discovery races ever faster, you need ... fast track. So our constant focus is on ... research. Thats why our Biomek 3000 Laboratory Automation ... advanced as it is flexible. By integrating all ...
... Zymeds MaxArray Rabbit Tissue Arrays contain 60 ... slides. Each package contains 4 unstained slides and ... your reference. Each slide contains 15 different tissues ... 60 tissue samples per slide. Each tissue sample ...
Biology Products: